Approximately 70% of 'triple-negative' breast cancers (ER negative, PR negative, Her2 negative) express basal markers [7-9], resulting in the triple-negative subtype commonly being used as a surrogate marker for the basal-like subtype. The gene discussed is ESR1; the disease is breast carcinoma.